Rubicon Genomics Adds New Member to its Board of Directors

Rubicon Genomics announced today that Timothy M. Mayleben has joined its Board of Directors. Mr. Mayleben most recently served as Chief Operating Officer and Chief Financial Officer of Esperion Therapeutics, Inc., a biopharmaceutical company acquired by Pfizer, Inc. in 2004.

“Tim brings a wealth of experience to our Board in finance, fund-raising and business development,” said Fred Beyerlein, President and CEO, Rubicon Genomics. “His deep understanding of company growth and development in our industry will add further depth to our Board.”

Mayleben will replace Richard Sloan, co-founder and financer of Rubicon. Mr. Sloan will transition to Board Observer status.

“We would also like to recognize Richard for his years of critical support on multiple levels, and we look forward to his ongoing participation,” added Beyerlein.

About Rubicon Genomics

Headquartered in Ann Arbor, Mich., USA, Rubicon Genomics, Inc. develops and commercializes the OmniPlex® family of amplification technologies for molecular diagnostics and research. GenomePlex™, MethylPlex™, and TransPlex™ are trademarks for Rubicon technologies to amplify trace amounts of DNA, methylated DNA and RNA. Rubicon’s partner, Sigma-Aldrich, sells GenomePlex™ kits to the research market. Rubicon discovers new cancer markers using MethylPlex™ and partners with pharmaceutical and diagnostic companies to co-develop more effective tests for cancer diagnosis and treatment. For more information, visit www.rubicongenomics.com.